EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...
The U.S. FDA paused Moderna's norovirus vaccine trial due to a rare side effect. U.S. Health Secretary Robert F. Kennedy Jr's initiatives may face budget cuts. Wyoming reports a human bird flu case.
The latest health briefs discuss the halt of Moderna’s norovirus vaccine trial, health policy changes under Robert F. Kennedy ...
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...